Please login to the form below

Not currently logged in
Email:
Password:

Fleishman-Hillard appoints Anne de Schweinitz to lead healthcare group

She replaces Michael Rinaldo and will relocate from the US to London

Fleishman-Hillard has appointed Anne de Schweinitz as senior vice president, senior partner and managing director of healthcare, and replace Michael Rinaldo, who recently left.

De Schweinitz has over 15-years experience in the healthcare industry will relocate from New York to Fleishman-Hillard's London office and will report directly to John Saunders, president of the agency's Europe/Middle East/Africa regions.

Commenting on her appointment Saunders said: “In addition to her exceptional business development track record and her skill in leveraging the resources of our agency network, Anne understands the importance of establishing sustainable and value-based relationships with clients, while cultivating the people-centric culture that sets Fleishman-Hillard apart.”

In her new role, de Schweinitz will also work closely with Nancy Seliger, executive vice president of global client relations, to help define and shape the firm's global healthcare group, establish thought-leadership initiatives, develop emerging growth opportunities and attract new marquee talent across all of Fleishman-Hillard's local and regional healthcare teams.

Before joining Fleishman-Hillard in 2011, de Schweinitz held leadership positions at Hill & Knowlton, Manning Selvage & Lee and Big Arrow Group – assignments that took her from San Francisco to London to New York.

She also spent several years handling communications duties for the University of California, San Francisco Medical Center.

8th May 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics